Compare BLNK & STTK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BLNK | STTK |
|---|---|---|
| Founded | 2009 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Specialties | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 129.3M | 119.0M |
| IPO Year | N/A | 2020 |
| Metric | BLNK | STTK |
|---|---|---|
| Price | $1.20 | $3.10 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 7 | 5 |
| Target Price | $2.13 | ★ $4.00 |
| AVG Volume (30 Days) | ★ 2.3M | 224.7K |
| Earning Date | 11-06-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $106,631,000.00 | $1,000,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $17.87 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.63 | $0.69 |
| 52 Week High | $2.65 | $3.12 |
| Indicator | BLNK | STTK |
|---|---|---|
| Relative Strength Index (RSI) | 37.12 | 79.66 |
| Support Level | $1.24 | $1.93 |
| Resistance Level | $1.43 | $2.18 |
| Average True Range (ATR) | 0.10 | 0.20 |
| MACD | 0.01 | 0.12 |
| Stochastic Oscillator | 6.90 | 98.42 |
Blink Charging Co is an owner, operator, and provider of electric vehicle (EV) charging services. The company offers both residential and commercial EV charging equipment, enabling EV drivers to easily recharge at various location types. The company's business is the sale and distribution of electric vehicle charging equipment and its associated revenues earned from customers and/or Property Partners who use equipment connected to its network. It earns a majority of revenue from U.S.A.
Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.